Samsung BioLogics lands $1.3 billion U.S. contract amid tariff uncertainty
1. $1.3 billion contract through 2029 makes this one of Samsung BioLogics’ largest agreements. 2. Expansion plans to nearly 1 ...
Tag: biologics
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup: Enbumyst Nasal Spray Approval, FDA Targets Drug Ads, Samsung BioLogics Contract, Wegovy Mental Health Benefits [September 17 2025]
Corstasis’ Enbumyst nasal spray approved for edema The Food and Drug Administration has approved Enbumyst, a bumetanide nasal spray, for ...
Use of risankizumab is effective in adult Crohn’s disease
1. In adult patients with Crohn’s disease (CD) treated with risankizumab, only 13% of patients experienced treatment failure while 23% ...
Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
1. In patients with previously treated metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with sacituzumab ...
Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with ...
Tofacitinib may be effective as a treatment of pediatric ulcerative colitis
1. Management of pediatric ulcerative colitis with tofacitinib successfully induced corticosteroid-free remission in 16% of patients at week 8 following ...
Dupilumab For Management of Bullous Pemphigoids
1. Dupilumab treatment for bullous pemphigoids resulted in improved clinical symptoms. 2. Patients with anti-BP180 antibody levels of at least ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
